These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26479291)

  • 1. RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.
    Serrano C; Romagosa C; Hernández-Losa J; Simonetti S; Valverde C; Moliné T; Somoza R; Pérez M; Vélez R; Vergés R; Domínguez R; Carles J; Ramón Y Cajal S
    Cancer; 2016 Jan; 122(1):99-107. PubMed ID: 26479291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
    Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
    Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
    Setsu N; Kohashi K; Fushimi F; Endo M; Yamamoto H; Takahashi Y; Yamada Y; Ishii T; Yokoyama K; Iwamoto Y; Oda Y
    Cancer; 2013 Oct; 119(19):3504-13. PubMed ID: 23861137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.
    Takahashi Y; Kohashi K; Yamada Y; Endo M; Setsu N; Ishii T; Yamamoto H; Iwamoto Y; Oda Y
    Hum Pathol; 2014 May; 45(5):984-93. PubMed ID: 24746202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.
    Setsu N; Yamamoto H; Kohashi K; Endo M; Matsuda S; Yokoyama R; Nishiyama K; Iwamoto Y; Dobashi Y; Oda Y
    Cancer; 2012 Mar; 118(6):1637-48. PubMed ID: 21837670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
    Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
    Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
    Bibollet-Bahena O; Almazan G
    J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
    Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
    Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior.
    Ferrandiz-Pulido C; Masferrer E; Toll A; Hernandez-Losa J; Mojal S; Pujol RM; Ramon y Cajal S; de Torres I; Garcia-Patos V
    J Urol; 2013 Dec; 190(6):2288-95. PubMed ID: 23764082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Undifferentiated pleomorphic sarcoma with co-existence of KRAS/PIK3CA mutations.
    Li B; Li L; Li X; Wang Y; Xie Y; Liu C; Li F
    Int J Clin Exp Pathol; 2015; 8(7):8563-7. PubMed ID: 26339434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
    Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
    Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival.
    Coutant A; Rescan C; Gilot D; Loyer P; Guguen-Guillouzo C; Baffet G
    Hepatology; 2002 Nov; 36(5):1079-88. PubMed ID: 12395317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential.
    Gleeson FC; Kipp BR; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Graham RP; Lazaridis KN; Henry MR; Levy MJ
    Gastrointest Endosc; 2015 Sep; 82(3):550-6.e1. PubMed ID: 25887718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer.
    Wiesweg M; Reis H; Köster T; Goetz M; Worm K; Herold T; Paul A; Dechêne A; Schumacher B; Markus P; Virchow I; Kostbade K; Wolf N; Zaun G; Metzenmacher M; Schmid KW; Schuler M; Kasper S
    Clin Colorectal Cancer; 2018 Jun; 17(2):e331-e352. PubMed ID: 29526493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.